Lonza Group AG (LZAGF)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
At close: 03:44PM EDT
| Previous close | 475.00 |
| Open | 483.78 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 467.30 - 483.78 |
| 52-week range | 439.65 - 673.62 |
| Volume | |
| Avg. volume | 723 |
| Market cap | 34.931B |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | 27.97 |
| EPS (TTM) | 16.77 |
| Earnings date | N/A |
| Forward dividend & yield | 3.94 (0.83%) |
| Ex-dividend date | 09 May 2023 |
| 1y target est | N/A |
Simply Wall St.Is Lonza Group AG (VTX:LONN) Worth CHF498 Based On Its Intrinsic Value?
Key Insights Lonza Group's estimated fair value is CHF410 based on 2 Stage Free Cash Flow to Equity Lonza Group is...
- Simply Wall St.
Lonza Group AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Lonza Group AG ( VTX:LONN ) missed earnings with its latest half-year results, disappointing overly-optimistic...
Business WireVertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
BOSTON & BASEL, Switzerland, June 26, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Lonza (SIX: LONN) today announced a strategic collaboration to support the manufacture of Vertex’s portfolio of investigational stem cell-derived, fully differentiated insulin-producing islet cell therapies for people with T1D, currently focusing on the VX-880 and VX-264 programs that are currently in clinical trials.
© 2023 Yahoo. All rights reserved.
